Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

720 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic value of pre-infusion tumor growth rate for patients with lymphoma receiving chimeric antigen receptor T-cell therapy.
Winkelmann M, Blumenberg V, Rejeski K, Quell C, Bücklein VL, Ingenerf M, Unterrainer M, Schmidt C, Dekorsy FJ, Bartenstein P, Ricke J, von Bergwelt-Baildon M, Subklewe M, Kunz WG. Winkelmann M, et al. Among authors: bartenstein p. Cytotherapy. 2023 Sep;25(9):986-992. doi: 10.1016/j.jcyt.2023.03.007. Epub 2023 Apr 11. Cytotherapy. 2023. PMID: 37055322
Prognostic value of the International Metabolic Prognostic Index for lymphoma patients receiving chimeric antigen receptor T-cell therapy.
Winkelmann M, Blumenberg V, Rejeski K, Bücklein VL, Ruzicka M, Unterrainer M, Schmidt C, Dekorsy FJ, Bartenstein P, Ricke J, von Bergwelt-Baildon M, Subklewe M, Kunz WG. Winkelmann M, et al. Among authors: bartenstein p. Eur J Nucl Med Mol Imaging. 2023 Apr;50(5):1406-1413. doi: 10.1007/s00259-022-06075-2. Epub 2022 Dec 14. Eur J Nucl Med Mol Imaging. 2023. PMID: 36513818
Cost-Effectiveness Analysis of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer.
Mehrens D, Kramer KKM, Unterrainer LM, Beyer L, Bartenstein P, Froelich MF, Tollens F, Ricke J, Rübenthaler J, Schmidt-Hegemann NS, Herlemann A, Unterrainer M, Kunz WG. Mehrens D, et al. Among authors: bartenstein p. J Natl Compr Canc Netw. 2023 Jan;21(1):43-50.e2. doi: 10.6004/jnccn.2022.7070. J Natl Compr Canc Netw. 2023. PMID: 36634610
Feasibility of radiomic feature harmonization for pooling of [18F]FET or [18F]GE-180 PET images of gliomas.
Zounek AJ, Albert NL, Holzgreve A, Unterrainer M, Brosch-Lenz J, Lindner S, Bollenbacher A, Boening G, Rupprecht R, Brendel M, von Baumgarten L, Tonn JC, Bartenstein P, Ziegler S, Kaiser L. Zounek AJ, et al. Among authors: bartenstein p. Z Med Phys. 2023 Feb;33(1):91-102. doi: 10.1016/j.zemedi.2022.12.005. Epub 2023 Jan 27. Z Med Phys. 2023. PMID: 36710156 Free PMC article.
An Analysis of the Distribution of PSMA PET/CT-Positive Lymph Nodes and Their Coverage by Different Elective Nodal Radiation Volumes in Postoperative Prostate Cancer Patients.
Trapp C, Oliinyk D, Rogowski P, von Bestenbostel R, Ganswindt U, Li M, Eze C, Bartenstein P, Beyer L, Ilhan H, Sheikh G, Unterrainer L, Stief C, Westhofen T, Kunz WG, Unterrainer M, Belka C, Schmidt-Hegemann NS. Trapp C, et al. Among authors: bartenstein p. J Nucl Med. 2023 Jun;64(6):918-923. doi: 10.2967/jnumed.122.265159. Epub 2023 Feb 2. J Nucl Med. 2023. PMID: 36732055 Free article.
High-Grade Glioma Radiation Therapy and Reirradiation Treatment Planning Using Translocator Protein Positron Emission Tomography With 18F-GE-180.
Fleischmann DF, Büttner M, Unterrainer M, Corradini S, Zollner B, Hofmaier J, Bodensohn R, Thon N, Belka C, Bartenstein P, Albert NL, Niyazi M. Fleischmann DF, et al. Among authors: bartenstein p. Adv Radiat Oncol. 2023 Jan 26;8(3):101185. doi: 10.1016/j.adro.2023.101185. eCollection 2023 May-Jun. Adv Radiat Oncol. 2023. PMID: 36896209 Free PMC article.
Development of PSMA-PET-guided CT-based radiomic signature to predict biochemical recurrence after salvage radiotherapy.
Spohn SKB, Schmidt-Hegemann NS, Ruf J, Mix M, Benndorf M, Bamberg F, Makowski MR, Kirste S, Rühle A, Nouvel J, Sprave T, Vogel MME, Galitsnaya P, Gschwend JE, Gratzke C, Stief C, Löck S, Zwanenburg A, Trapp C, Bernhardt D, Nekolla SG, Li M, Belka C, Combs SE, Eiber M, Unterrainer L, Unterrainer M, Bartenstein P, Grosu AL, Zamboglou C, Peeken JC. Spohn SKB, et al. Among authors: bartenstein p. Eur J Nucl Med Mol Imaging. 2023 Jul;50(8):2537-2547. doi: 10.1007/s00259-023-06195-3. Epub 2023 Mar 16. Eur J Nucl Med Mol Imaging. 2023. PMID: 36929180 Free PMC article.
Metabolic patterns on [18F]FDG PET/CT in patients with unresectable stage III NSCLC undergoing chemoradiotherapy ± durvalumab maintenance treatment.
Holzgreve A, Taugner J, Käsmann L, Müller P, Tufman A, Reinmuth N, Li M, Winkelmann M, Unterrainer LM, Nieto AE, Bartenstein P, Kunz WG, Ricke J, Belka C, Eze C, Unterrainer M, Manapov F. Holzgreve A, et al. Among authors: bartenstein p. Eur J Nucl Med Mol Imaging. 2023 Jul;50(8):2466-2476. doi: 10.1007/s00259-023-06192-6. Epub 2023 Mar 23. Eur J Nucl Med Mol Imaging. 2023. PMID: 36951991 Free PMC article.
Validation of the SSTR-RADS 1.0 for the structured interpretation of SSTR-PET/CT and treatment planning in neuroendocrine tumor (NET) patients.
Grawe F, Ebner R, Geyer T, Beyer L, Winkelmann M, Sheikh GT, Eschbach R, Schmid-Tannwald C, Cyran CC, Ricke J, Bartenstein P, Heimer MM, Faggioni L, Spitzweg C, Fabritius MP, Auernhammer CJ, Ruebenthaler J. Grawe F, et al. Among authors: bartenstein p. Eur Radiol. 2023 May;33(5):3416-3424. doi: 10.1007/s00330-023-09518-y. Epub 2023 Mar 25. Eur Radiol. 2023. PMID: 36964768 Free PMC article.
Staging of lymphoma under chimeric antigen receptor T-cell therapy: reasons for discordance among imaging response criteria.
Winkelmann M, Blumenberg V, Rejeski K, Bücklein VL, Ingenerf M, Unterrainer M, Schmidt C, Dekorsy FJ, Bartenstein P, Ricke J, von Bergwelt-Baildon M, Subklewe M, Kunz WG. Winkelmann M, et al. Among authors: bartenstein p. Cancer Imaging. 2023 May 15;23(1):44. doi: 10.1186/s40644-023-00566-7. Cancer Imaging. 2023. PMID: 37189191 Free PMC article.
720 results